Contribution
Everyone should have the right of access to high-quality, evidence-based healthcare, whatever their age. At the heart of this debate are young people experiencing profound gender-related distress, and the families who support them. Too often they have found themselves caught in the middle of a political argument while facing long waits, uncertainty, and a lack of clear treatment options. Every young person deserves compassionate, evidence-based care, and that includes transgender young people and children with gender incongruence.
The irony of the Opposition motion is that it would stop the very research that many Members have argued is necessary before decisions about treatment can be made. If we are serious about evidence-based medicine, we must also be serious about gathering evidence. The Pathways trial follows a recommendation made by Baroness Cass in her independent review, a recommendation that had enjoyed cross-party support when it was published. Since then the trial has undergone extensive scrutiny by researchers, ethics committees, independent reviewers and regulators. Following further modifications and additional safeguards, it has been approved by both the Medicines and Healthcare products Regulatory Agency and the Health Research Authority. If Members believe that more evidence is needed, surely they should support a process that is designed to produce that evidence.
Much has been said about risk, and of course risk must be taken seriously, but the answer to uncertainty cannot simply be to refuse to learn more. The answer is careful, closely monitored research with robust protections. Participants must have experienced gender incongruence for at least two years, must already be receiving NHS gender services, must have undergone psychosocial support, and must be assessed as being physically and mentally stable. Both the young people and their parents must consent, and every participant must be approved by clinicians and a national multidisciplinary team. This is not an uncontrolled experiment; it is a tightly regulated clinical trial operating under some of the highest standards of oversight that are available in modern medicine.
The hon. Member for Reigate (Rebecca Paul) made a valid point about the need to ensure that children who realise that they are gay do not decide that they are transgender, and that we do not feel that we should push more gay people back into the closet, as they are feeling very much under threat at present. However, there is another risk that we must discuss, and that is inaction. For two years, puberty blockers have effectively been unavailable outside research settings. Young people and their families have been told repeatedly that more evidence is needed, and now, when a trial designed to generate that evidence is ready to proceed, some seek to stop it. What message does that send?
Behind every statistic is a family. Parents of transgender children and children with gender incongruence often speak of the distress of watching their child struggle and feeling powerless to help. They see anxiety, fear and growing distress as their child experiences physical changes that can feel deeply uncomfortable and alienating. These families are not political talking points; they are looking for support, answers and hope. For many transgender young people, puberty itself can be a source of profound distress. We should not pretend that doing nothing is a neutral act, because delays, uncertainty and the absence of treatment options have consequences too. Puberty blockers have generally been understood as a reversible intervention intended to pause puberty and provide time for further assessment and support, and the purpose of this trial is to strengthen our understanding of both the benefits and the risks. If opponents argue that more evidence is needed, blocking the research that would provide that evidence is a contradiction that this House should reject.
I also want to address something that often sits beneath debates such as this. If you come to this debate from the position that transgender people do not exist or that it is a fad, you are mistaken. Transgender people have always existed, and they deserve the same dignity, compassion and evidence-based healthcare as anyone else. If, as I believe we all do, we come to the debate motivated by concern for children’s safety and wellbeing, how can we say that we are protecting children while being comfortable with them living in fear of the changes that puberty may bring? How can we say that we are acting in their best interests when some young people are terrified of growing into an adult body that does not align with who they understand themselves to be, while parents watch helplessly from the sideline? If our goal is to truly safeguard children, we should support careful research, rigorous oversight and evidence-based medicine. We should seek answers, not prevent them. We should reduce uncertainty, not prolong it. That is why this trial should proceed.